Targeting surface protein SasX by active and passive vaccination to reduce Staphylococcus aureus colonization and infection

Infection and Immunity

Volumn 83, Issue 5, 2015, Pages 2168-2174

  Liu, Qian ^a   Du, Xin ^b   Hong, Xufen ^b   Li, Tianming ^a   Zheng, Bing ^a   He, Lei ^a   Wang, Yanan ^a   Otto, Michael ^c   Li, Min ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; BACTERIUM ANTIBODY; CYTOKINE; FREUND ADJUVANT; IMMUNOGLOBULIN G; MEMBRANE PROTEIN; SASX PROTEIN; STAPHYLOCOCCUS VACCINE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ACTIVE IMMUNIZATION; ACUTE LUNG INJURY; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL IMMUNITY; BACTERIAL STRAIN; BACTERIUM ISOLATE; COLONY FORMING UNIT; CONTROLLED STUDY; FEMALE; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NEUTROPHIL CHEMOTAXIS; NONHUMAN; PASSIVE IMMUNIZATION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; STAPHYLOCOCCAL SKIN INFECTION; STAPHYLOCOCCUS AUREUS; ANIMAL; BAGG ALBINO MOUSE; BLOOD; DISEASE MODEL; HETEROZYGOTE; IMMUNOLOGY; MICROBIOLOGY; NOSE MUCOSA; PATHOLOGY; PNEUMONIA, BACTERIAL; PREVENTION AND CONTROL; PROCEDURES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; VACCINATION;

ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; CARRIER STATE; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION, PASSIVE; IMMUNOGLOBULIN G; MEMBRANE PROTEINS; MICE, INBRED BALB C; NASAL MUCOSA; PNEUMONIA, BACTERIAL; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCAL SKIN INFECTIONS; STAPHYLOCOCCAL VACCINES; STAPHYLOCOCCUS AUREUS; VACCINATION; VIRULENCE FACTORS;

EID: 84928200446     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.02951-14     Document Type: Article

References (27)

1. Lowy FD. 1998. Staphylococcus aureus infections. N Engl J Med 339:520-532. http://dx.doi.org/10.1056/NEJM199808203390806.
2. Centers for Disease Control and Prevention. 2013. Antibiotic resistance threats in the United States, 2013. CDC, Atlanta, GA. http://www.cdc.gov/drugresistance/threat-report-2013.
3. Lowy FD. 2003. Antimicrobial resistance: theexampleof Staphylococcus aureus. J Clin Invest 111:1265-1273. http://dx.doi.org/10.1172/JCI200318535.
4. Schaffer AC, Lee JC. 2009. Staphylococcal vaccines and immunotherapies. Infect Dis Clin North Am 23:153-171. http://dx.doi.org/10.1016/j.idc.2008.10.005.
5. DeLeo FR, Otto M. 2008. An antidote for Staphylococcus aureus pneumonia? J Exp Med 205:271-274. http://dx.doi.org/10.1084/jem.20080167.
6. Rooijakkers SH, van Kessel KP, van Strijp JA. 2005. Staphylococcal innate immune evasion. Trends Microbiol 13:596-601. http://dx.doi.org/10.1016/j.tim.2005.10.002.
7. DeLeo FR, Chambers HF. 2009. Reemergence of antibiotic-resistant Staphylococcus aureus in the genomics era. J Clin Invest 119:2464-2474. http://dx.doi.org/10.1172/JCI38226.
8. Liu Y, Wang H, Du N, Shen E, Chen H, Niu J, Ye H, Chen M. 2009. Molecular evidence for spread of two major methicillin-resistant Staphylococcus aureus clones with a unique geographic distribution in Chinese hospitals. Antimicrob Agents Chemother 53:512-518. http://dx.doi.org/10.1128/AAC.00804-08.
9. Holden MT, Lindsay JA, Corton C, Quail MA, Cockfield JD, Pathak S, Batra R, Parkhill J, Bentley SD, Edgeworth JD. 2010. Genome sequence of a recently emerged, highly transmissible, multi-antibiotic- and antisepticresistant variant of methicillin-resistant Staphylococcus aureus, sequence type 239 (TW). J Bacteriol 192:888-892. http://dx.doi.org/10.1128/JB.01255-09.
10. Li M, Du X, Villaruz AE, Diep BA, Wang D, Song Y, Tian Y, Hu J, Yu F, Lu Y, Otto M. 2012. MRSA epidemic linked to a quickly spreading colonization and virulence determinant. Nat Med 18:816-819. http://dx.doi.org/10.1038/nm.2692.
11. Kobayashi SD, Voyich JM, Buhl CL, Stahl RM, DeLeo FR. 2002. Global changes in gene expression by human polymorphonuclear leukocytes during receptor-mediated phagocytosis: cell fate is regulated at the level of gene expression. Proc Natl Acad Sci U S A 99:6901-6906. http://dx.doi.org/10.1073/pnas.092148299.
12. Li M, Cheung GY, Hu J, Wang D, Joo HS, DeLeo FR, Otto M. 2010. Comparative analysis of virulence and toxin expression of global community-associated methicillin-resistant Staphylococcus aureus strains. J Infect Dis 202:1866-1876. http://dx.doi.org/10.1086/657419.
13. Malaviya R, Ikeda T, Ross E, Abraham SN. 1996. Mast cell modulation of neutrophil influx and bacterial clearance at sites of infection through TNF-alpha. Nature 381:77-80. http://dx.doi.org/10.1038/381077a0.
14. Nakamura Y, Oscherwitz J, Cease KB, Chan SM, Munoz-Planillo R, Hasegawa M, Villaruz AE, Cheung GY, McGavin MJ, Travers JB, Otto M, Inohara N, Nunez G. 2013. Staphylococcus delta-toxin induces allergic skin disease by activating mast cells. Nature 503:397-401. http://dx.doi.org/10.1038/nature12655.
15. Voyich JM, Otto M, Mathema B, Braughton KR, Whitney AR, Welty D, Long RD, Dorward DW, Gardner DJ, Lina G, Kreiswirth BN, DeLeo FR. 2006. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease? J Infect Dis 194:1761-1770. http://dx.doi.org/10.1086/509506.
16. Rigby KM, DeLeo FR. 2012. Neutrophils in innate host defense against Staphylococcus aureus infections. Semin Immunopathol 34:237-259. http://dx.doi.org/10.1007/s00281-011-0295-3.
17. Otto M. 2014. Staphylococcus aureus toxins. Curr Opin Microbiol 17:32-37. http://dx.doi.org/10.1016/j.mib.2013.11.004.
18. Malaviya R, Ikeda T, Ross EA, Jakschik BA, Abraham SN. 1995. Bacteria-mast cell interactions in inflammatory disease. Am J Therap 2:787-792.
19. Wertheim HF, Melles DC, Vos MC, van Leeuwen W, van Belkum A, Verbrugh HA, Nouwen JL. 2005. The role of nasal carriage in Staphylococcus aureus infections. Lancet Infect Dis 5:751-762. http://dx.doi.org/10.1016/S1473-3099(05)70295-4.
20. von Eiff C, Becker K, Machka K, Stammer H, Peters G. 2001. Nasal carriage as a source of Staphylococcus aureus bacteremia. Study GroupNEngl J Med 344:11-16. http://dx.doi.org/10.1056/NEJM200101043440102.
21. Hilliard JJ, Datta V, Tkaczyk C, Hamilton M, Sadowska A, Jones-Nelson O, O'Day T, Weiss WJ, Szarka S, Nguyen V, Prokai L, Suzich J, Stover CK, Sellman BR. 2015. Anti-alpha toxin monoclonal antibody and antibiotic combination therapy improves disease outcome and accelerates healing in a Staphylococcus aureus dermonecrosis model. Antimicrob Agents Chemother 59:299-309. http://dx.doi.org/10.1128/AAC.03918-14.
22. Pozzi C, Wilk K, Lee JC, Gening M, Nifantiev N, Pier GB. 2012. Opsonic and protective properties of antibodies raised to conjugate vaccines targeting six Staphylococcus aureus antigens. PLoS One 7:e46648. http://dx.doi.org/10.1371/journal.pone.0046648.
23. Wertheim HF, Walsh E, Choudhurry R, Melles DC, Boelens HA, Miajlovic H, Verbrugh HA, Foster T, van Belkum A. 2008. Key role for clumping factor B in Staphylococcus aureus nasal colonization of humans. PLoS Med 5:e17. http://dx.doi.org/10.1371/journal.pmed.0050017.
24. Clarke SR, Brummell KJ, Horsburgh MJ, McDowell PW, Mohamad SA, Stapleton MR, Acevedo J, Read RC, Day NP, Peacock SJ, Mond JJ, Kokai-Kun JF, Foster SJ. 2006. Identification of in vivo-expressed antigens of Staphylococcus aureus and their use in vaccinations for protection against nasal carriage. J Infect Dis 193:1098-1108. http://dx.doi.org/10.1086/501471.
25. Maurer M, von Stebut E. 2004. Macrophage inflammatory protein-1. Int J Biochem Cell Biol 36:1882-1886. http://dx.doi.org/10.1016/j.biocel.2003.10.019.
26. Schlageter AM, Kozel TR. 1990. Opsonization of Cryptococcus neoformans by a family of isotype-switch variant antibodies specific for the capsular polysaccharide. Infect Immun 58:1914-1918.
27. Otto M. 2010. Novel targeted immunotherapy approaches for staphylococcal infection. Expert Opin Biol Ther 10:1049-1059. http://dx.doi.org/10.1517/14712598.2010.495115.